Table 5 Delay of doses or dose reductions in carboplatin or doxorubicin associated with the combination of taurolidine
From: Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma
Dose delay | Case # | Caused by taurolidine combined with | Number of times for delay or reduction | Reason/circumstances |
|---|---|---|---|---|
10 | Carboplatin | 2 | Neutropenia | |
1 | Had been neutropenic previous 2 times so delayed dose without checking neutrophils at 21 days post treatment | |||
9 | Doxorubicin | 1 | Renal insufficiency | |
7 | Doxorubicin | 1 | Lethargy and inappetance | |
8 | Doxorubicin | 1 | Limb edema | |
12 | Carboplatin | 1 | Neutropenia: taurolidine had been given 9 days after the carboplatin treatment | |
9 | Carboplatin | 1 | Owner’s restrictions | |
11 | Carboplatin | 1 | ||
12 | Carboplatin | 1 | ||
Dose reduction | ||||
7 | Doxorubicin | 2 | Lethargy and inappetance throughout chemotherapy period | |
9 | Doxorubicin | 4 | Dose reduction was done for the all carboplatin treatments due to the renal insufficiency that the dog had developed after the combination with doxorubicin | |
10 | Carboplatin | 1 | Neutropenia |